CN119110810A - MHC Ib介导的水通道蛋白4（AQP4）特异性免疫抑制作为NMO的新型治疗方法 - Google Patents

MHC Ib介导的水通道蛋白4（AQP4）特异性免疫抑制作为NMO的新型治疗方法 Download PDF

Info

Publication number
CN119110810A
CN119110810A CN202380029744.3A CN202380029744A CN119110810A CN 119110810 A CN119110810 A CN 119110810A CN 202380029744 A CN202380029744 A CN 202380029744A CN 119110810 A CN119110810 A CN 119110810A
Authority
CN
China
Prior art keywords
amino acid
recombinant polypeptide
seq
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380029744.3A
Other languages
English (en)
Chinese (zh)
Inventor
瓦伦汀·布鲁塔尔
乔戈·维施胡森
施瑞娅·玛玛萨·贾亚拉姆
法德赫·阿赫桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Würzburg
Original Assignee
University of Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Würzburg filed Critical University of Würzburg
Publication of CN119110810A publication Critical patent/CN119110810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380029744.3A 2022-03-24 2023-03-24 MHC Ib介导的水通道蛋白4（AQP4）特异性免疫抑制作为NMO的新型治疗方法 Pending CN119110810A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164161.6A EP4249062A1 (en) 2022-03-24 2022-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EP22164161.6 2022-03-24
PCT/EP2023/057684 WO2023180549A1 (en) 2022-03-24 2023-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Publications (1)

Publication Number Publication Date
CN119110810A true CN119110810A (zh) 2024-12-10

Family

ID=81325683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380029744.3A Pending CN119110810A (zh) 2022-03-24 2023-03-24 MHC Ib介导的水通道蛋白4（AQP4）特异性免疫抑制作为NMO的新型治疗方法

Country Status (12)

Country Link
US (1) US20250205322A1 (enExample)
EP (2) EP4249062A1 (enExample)
JP (1) JP2025510786A (enExample)
KR (1) KR20240164796A (enExample)
CN (1) CN119110810A (enExample)
AU (1) AU2023237632A1 (enExample)
CA (1) CA3250911A1 (enExample)
CL (1) CL2024002725A1 (enExample)
CO (1) CO2024012332A2 (enExample)
IL (1) IL314754A (enExample)
MX (1) MX2024011666A (enExample)
WO (1) WO2023180549A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061917A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234017B2 (en) * 2012-12-11 2016-01-12 The Regents Of The University Of California Aquaporin-4 peptide compositions and methods of use thereof
SG11201909290TA (en) * 2017-04-07 2019-11-28 Uti Lp Assay to measure the potency of receptor-ligand interactions in nanomedicines
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
WO2021184017A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders

Also Published As

Publication number Publication date
CO2024012332A2 (es) 2024-09-30
CA3250911A1 (en) 2023-09-28
US20250205322A1 (en) 2025-06-26
EP4249062A1 (en) 2023-09-27
KR20240164796A (ko) 2024-11-20
WO2023180549A1 (en) 2023-09-28
MX2024011666A (es) 2024-09-27
AU2023237632A1 (en) 2024-08-15
CL2024002725A1 (es) 2025-02-14
EP4499231A1 (en) 2025-02-05
IL314754A (en) 2024-10-01
JP2025510786A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
Rodriguez‐Manzanet et al. The costimulatory role of TIM molecules
JP2024138456A (ja) 改変された制御性ｔ細胞
TW201806969A (zh) 嵌合抗原受體
JP2023052647A (ja) 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
TWI918761B (zh) 冷凍保存經工程化之調節t細胞(tregs)之方法
KR20140116054A (ko) 다발성 경화증의 치료를 위한 ａｐｃ-매개 관용 유도
WO2024110751A1 (en) Constitutively active chimeric antigen receptor for treg cell survival and/or persistence
US20250205322A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
JPH10501888A (ja) 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US20250222083A1 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
CN119317639A (zh) MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法
AU2024346292A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EP4172213A1 (en) Methods and compositions for the reduction of chimeric antigen receptor tonic signaling
US20250205323A1 (en) Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
Seta et al. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals
TW202519540A (zh) MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療
EP4416293A1 (en) Modified binding proteins and therapeutic uses thereof
Ohaegbulam Tumoral B7x promotes pulmonary metastases independent of direct Neuropilin-1 interaction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination